Otsuka has been granted a patent for a protective agent for keratoconjunctiva containing glucosylglycerol. The method involves administering an ophthalmic formulation with glucosylglycerol to protect against dry eye. GlobalData’s report on Otsuka gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Otsuka, was a key innovation area identified from patents. Otsuka's grant share as of May 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Ophthalmic formulation for protecting keratoconjunctiva from dry eye
A recently granted patent (Publication Number: US12005070B2) discloses a method for protecting the keratoconjunctiva from dry eye in a subject by administering an ophthalmic formulation containing glucosylglycerol and an ophthalmically acceptable carrier. The glucosylglycerol is present in the formulation in an amount ranging from 0.01 to 10% by mass, providing a novel approach to addressing dry eye conditions.
Furthermore, the patent claims encompass a method for treating dry eye in a subject by administering an ophthalmic formulation containing glucosylglycerol and an ophthalmically acceptable carrier. The glucosylglycerol, which can be 1-a-glyceryl glucoside, 2-a-glyceryl glucoside, 1-ß-glyceryl glucoside, 2-ß-glyceryl glucoside, or a mixture thereof, is crucial in alleviating dry eye symptoms. This innovative method offers a promising solution for individuals suffering from dry eye, highlighting the potential of glucosylglycerol in ophthalmic formulations for therapeutic purposes.
To know more about GlobalData’s detailed insights on Otsuka, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.